UnknownNCT05099978
Asian Multicenter Prospective Study of ctDNA Sequencing
Studying Clear cell adenocarcinoma of the ovary
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Center, Japan
- Principal Investigator
- Kan Yonemori, MD, PhDDepartment of Medical Oncology, National Cancer Cancer Hospital
- Intervention
- NGS analysis of ctDNA(genetic)
- Enrollment
- 506 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2024
Study locations (19)
- National Cancer Center Hospital, Tokyo, Japan
- Sarawak General Hospital, Kuching, Sarawak, Malaysia
- University Malaya Medicine Centre, Kuala Lumpur, Selangor, Malaysia
- Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
- Institut Kanser Negara, Putrajaya, Malaysia
- St. Luke's Medical Center, Manila, Philippines
- National Cancer Centre of Singapore, Bukit Merah, Singapore
- National University Hopital, Kent Ridge, Singapore
- Severance Hospital, Yonsei University Health System, Seoul, South Korea
- National Taiwan University Hospital, Taipei, Zhongzheng Dist, Taiwan
- Vajira Hospital, Bangkok, Thailand
- Chulalongkorn University, Bangkok, Thailand
- Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
- Phramongkutklao Hospital, Bangkok, Thailand
- Mahidol University by Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05099978 on ClinicalTrials.govOther trials for Clear cell adenocarcinoma of the ovary
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06677190Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginDana-Farber Cancer Institute
- RECRUITINGPHASE1, PHASE2NCT06065462Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100M.D. Anderson Cancer Center
- RECRUITINGNCT06279104A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the OvaryTongji Hospital
- ACTIVE NOT RECRUITINGPHASE2NCT05296512Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerElizabeth K. Lee MD
- ACTIVE NOT RECRUITINGPHASE2NCT05032040A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary MalignanciesXencor, Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc.
- RECRUITINGPHASE1, PHASE2NCT04104776A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGPHASE2NCT03348631Tazemetostat in Treating Patients With Recurrent Ovarian or Endometrial CancerNational Cancer Institute (NCI)